Header Logo

Connection

CHARLES WYKOFF to Biosimilar Pharmaceuticals

Back to Details
This is a "connection" page, showing publications CHARLES WYKOFF has written about Biosimilar Pharmaceuticals.
CHARLES WYKOFF
Connection Strength
0.206
Biosimilar Pharmaceuticals
  1. Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 2023 06; 8(1).
    View in: PubMed
    Score: 0.206
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.